Muscular Dystrophy, Facioscapulohumeral clinical trials
The registry lists 79 studies for Muscular Dystrophy, Facioscapulohumeral across more than 10 countries. 26 are recruiting or about to start. 60 of them are mainly about Muscular Dystrophy, Facioscapulohumeral (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Muscular Dystrophy, Facioscapulohumeral studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Centre Hospitalier Universitaire de Nice (8) · aTyr Pharma, Inc. (5) · University of Rochester (3) · Fulcrum Therapeutics (3) · Avidity Biosciences, Inc. (3) · LMU Klinikum (3) · University of Kansas Medical Center (3) · Radboud University Medical Center (2)
What is being tested here
Drugs under test in Muscular Dystrophy, Facioscapulohumeral studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8
- Jan 2027Magnetic Resonance Imaging and Ultrasound Comparison With Load Evaluation · Radboud University Medical Center
- Mar 2027Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1 · Centre Hospitalier Universitaire de Nice
- Apr 2027ADVANCED FSHD-COM: New Clinical Outcome Measures to Evaluate Non-ambulant FSHD Patients, a Pilot Study · Centre Hospitalier Universitaire de Nice
- May 2027Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) · University of Kansas Medical Center
- May 2027The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. · LMU Klinikum
- Jun 2027Biomarker Development for Muscular Dystrophies · Massachusetts General Hospital
- Jul 2027A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy · Epicrispr Biotechnologies, Inc.
- Aug 2027Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders · LMU Klinikum
Who these studies take
Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger. 10 (53%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (32%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 8 (42%) | 8 (42%) |
| 18 | 18 (95%) | 18 (95%) |
| 30 | 18 (95%) | 18 (95%) |
| 40 | 18 (95%) | 18 (95%) |
| 50 | 18 (95%) | 18 (95%) |
| 65 | 16 (84%) | 16 (84%) |
| 75 | 12 (63%) | 12 (63%) |
| 85 | 9 (47%) | 9 (47%) |
Across all 79 studies, recruiting or not: 56% stop at 75 or younger and 35% at 65; 30% take children; 0% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Muscular Dystrophy, Facioscapulohumeral studies take
Of 19 interventional studies with no phase under Muscular Dystrophy, Facioscapulohumeral, half reached primary completion within 21 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 21 mo13–39 · 19 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 79. Browse all 79 → or search them.
- A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHDRecruitingNCT07798609Phase 1/22 countries
- Biomarker Development for Muscular DystrophiesRecruitingNCT050196251 country
- Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)RecruitingNCT07086521Phase 11 country
- A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)Not yet recruitingNCT07872306Phase 2
- Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1Enrolling by invitationNCT06131983Phase 1/27 countries
- An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease ProgressionRecruitingNCT06079567Not applicable5 countries
- Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDRecruitingNCT07435129Phase 21 country
- The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient RegistryRecruitingNCT040015821 country
- A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDRecruitingNCT07038200Phase 310 countries
- Personalized Training for People With Rare Neuromuscular DisordersRecruitingNCT06708468Not applicable1 country
- Amino Acids and Exercise in FSHDRecruitingNCT07543016Not applicable1 country
- Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)RecruitingNCT068472822 countries
- Clenbuterol to Target DUX4 in FSHDRecruitingNCT06721299Phase 11 country
- BetterLife FSHD: A Patient-driven Health and Research PlatformRecruitingNCT074091421 country
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryRecruitingNCT000821081 country
- Imaging and Gait Analysis in FSHD PatientsEnrolling by invitationNCT071649371 country
- Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular DisordersEnrolling by invitationNCT066056121 country
- Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic PathologyRecruitingNCT07136844Not applicable1 country
- The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.Enrolling by invitationNCT07072676Not applicable1 country
- Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next StudyRecruitingNCT05982119Not applicable7 countries
- Muscle MRI Outlining of Neuromuscular Diseases Using Artificial IntelligenceNot yet recruitingNCT06917430
- Ten Year Follow-up in FSHD: the FOCUS 3 StudyRecruitingNCT069111901 country
- Magnetic Resonance Imaging and Ultrasound Comparison With Load EvaluationRecruitingNCT062271821 country
- A Registered Cohort Study on FSHD1RecruitingNCT043692091 country
- Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI]RecruitingNCT06378203Not applicable1 country
- Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through MetabolomicsNot yet recruitingNCT06086548
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseActive, not recruitingNCT07478172Not applicable1 country
- A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular DystrophyCompletedNCT05548556Phase 24 countries
- Clinical Trial Readiness to Solve Barriers to Drug Development in FSHDActive, not recruitingNCT034588326 countries
- The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular DisorderCompletedNCT06363357Not applicable1 country
- A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyActive, not recruitingNCT06907875Phase 1/23 countries
- Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular DystrophyActive, not recruitingNCT016718651 country
- Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedNCT05747924Phase 1/23 countries
- Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)Active, not recruitingNCT06547216Phase 23 countries
- Dietary Protein Requirements in Adults With Facioscapulohumeral Muscular DystrophyCompletedNCT06785428Not applicable1 country
- Computerized Facial Recognition for Automated Diagnosis of the Facio-Scapulo-Humeral Muscular Dystrophy (FSMHD)CompletedNCT04377217Not applicable1 country
- Quantitative Assessment of Orofacial Muscle Function in FSHDCompletedNCT06425445Not applicable1 country
- New Clinical Outcome Measures to Remotely Evaluate Patients With FacioScapuloHumeral Muscular DystrophyCompletedNCT05812144Not applicable1 country
- Ultrasound Detection of Early Facial Muscle Changes in FSHD: Thickness and Echo Intensity FindingsCompletedNCT073310251 country
- Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)TerminatedNCT05397470Phase 39 countries
- Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)TerminatedNCT04264442Phase 24 countries
- ADVANCED FSHD-COM: New Clinical Outcome Measures to Evaluate Non-ambulant FSHD Patients, a Pilot StudyActive, not recruitingNCT05453461Not applicable1 country
- FSHD Molecular CharacterizationTerminatedNCT060964411 country
- Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1Active, not recruitingNCT06222827Phase 22 countries
- The Risk of Falls Index for Patients With Neuromuscular DisordersCompletedNCT058908331 country
- Disease Burden and Living Situation of Patients With Facioscapulohumeral Muscular DystrophyStatus unknownNCT065174981 country
- Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedNCT04003974Phase 24 countries
- At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic ConditionsCompletedNCT019316441 country
- Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedNCT02836418Phase 1/23 countries
- Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2CompletedNCT02032979Not applicable1 country